Chemical Structure (Anastrozole 01)
Anastrozole Tablet
Product Images NDC 50090-5002
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 50090-5002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Anastrozole 02)
Figure 2 (Anastrozole 03)
The given text seems to be a graph that represents the proportion of patients who are alive and disease-free with respect to the treatment of breast cancer. The graph presents a comparison between treatment with the drug Anastrozole and Tamoxifen. The horizontal axis represents the time in months, and the vertical axis represents the proportion alive and disease-free. The number of patients at risk is also shown for both types of treatment.*
Figure 3 (Anastrozole 04)
This appears to be a truncated Kaplan-Meier curve showing the time to event (in months) for patients who received randomized treatment with either anastrozole or tamoxifen. The number of patients at risk is also shown for various months. The text seems to have some errors and inconsistent characters, making parts of it unreadable.*
Figure 4 (Anastrozole 05)
This is a Kaplan-Meier survival curve for patients being randomized to receive Anastrozole or Tamoxifen. The horizontal axis represents the time to an event in months, while the vertical axis represents the proportion of patients with event-free survival. The text contains some data points and the number of patients at risk, but the details of the study are not available.*
Figure 5 (Anastrozole 06)
This is a medical graph that shows the progression of a randomized treatment method using two drugs, Anastrozole and Tamoxifen, for an unspecified condition. The x-axis of the graph shows the time to progression in months, ranging from 0 to 32 months. The y-axis shows the proportion of patients who did not progress. The graph suggests that the proportion of patients who did not progress remained relatively stable throughout the course of the treatment.*
Figure 6 (Anastrozole 07)
This is a medical chart depicting the time to progression in months for randomized treatment on ANASTROZOLE and TAMOXIFEN. However, the rest of the text is not available for interpretation.*
Label Image (Lbl500905002)
This appears to be a product label for a medication called "AstroZOLE 1mg", with 30 tablets per container, and the product number is 6198-0. The medication may be used to treat hormone receptor positive breast cancer. The label also includes an address for "Stone AT" at 6810 7 Decces, but it is unclear what this refers to without further context.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
